Celebrating 70 years of commitment
Ferring is celebrating a number of anniversaries this year, most significantly the 70th anniversary of the company. Frederik and Eva Paulsen first founded the company in 1950, and the subsequent decades have witnessed the same pioneering spirit that continues to create life-changing treatments for people who need them.
The Ferring story is one that began with two exceptional scientists and entrepreneurs who believed that human peptide hormones could be harnessed to develop medicine on the body’s own terms. Here are just some of that journey’s highlights:
- From 60 square metres to 60 countries. From its beginnings in a small rented space of 60 square metres in Malmö, Sweden, Ferring operates in over 60 countries today.
- First scientific break-through. By 1961 the company had succeeded in producing synthetic peptide hormones (oxytocin and vasopressin) on an industrial scale, one of the first in the World to do so.
- Striking roots beyond Scandinavia. In 1973, Ferring established its first manufacturing presence outside Scandinavia, in Kiel, Germany.
- New therapies, new markets. In the next ten years, the company successfully launched its therapy for the treatment of bleeding oesophageal varices, and continued its expansion in Europe, North America and Asia.
- Supporting science in the community.In 1983, Dr Paulsen helped to initiate the Kiel Ferring Foundation, which provides a financial award to two students every two years, at the Faculty of Medicine at the Christian Albrechts-University in Kiel, in the field of endocrinology.
- Advancing frontiers in gastroenterology through the launch of a treatment for inflammatory bowel disease (IBD) in 1986.
- Double digit growth by 1990, as Ferring expanded further into Eastern Europe, South America and the Middle East, bringing new opportunities to treat new patients.
- A new decade brings new treatments in the area of fertility and growth hormone deficiency (GHD) in children and for the treatment of girls with Turner’s syndrome.
- By 2000, Ferring research led to a new treatment for pre-term labour, and further developments in fertility treatment, to help more people build families.
- The following decade included the opening of new headquarters and production facilities at St-Prex, Switzerland and the launch of a new therapy for advanced hormone-dependent prostate cancer.
- Growth accelerated as Ferring launched five additional products between 2013-2018 in the areas of reproductive medicine and maternal health, gastroenterology and endocrinology.
- Ferring entered new therapeutic frontiers with its acquisition of Rebiotix, a leader in microbiota therapy in 2018.
- New possibilities with gene therapy for bladder cancer patients emerge as Ferring enters into a global agreement to commercialise an investigational gene therapy.
- One of our proudest moments. Ferring’s heat-stable carbetocin added to the WHO List of Essential Medicines in 2019 for the treatment of postpartum haemorrhage (PPH).
- Over 3.2 million babies have been born worldwide thanks to Ferring treatments.
Next year must focus on delivering against Purpose, People and Planet in even more tangible ways…this is the decade that must make the difference.
President of Ferring Pharmaceuticals